Lessons from the ASPIRE trial: three drug regimens as the new SOC for relapsed MM
Understanding science and research: the importance of patient advocates
Overcoming mental health issues for patients with CLL
Are we ready to use minimal residual disease (MRD) to direct multiple myeloma therapy?
A novel WINDOW of opportunity for young mantle cell lymphoma patients